Synthes Bone Void Filler Off-Label Concerns, MDR Gaps Elicit FDA Warning
This article was originally published in The Gray Sheet
Executive Summary
Synthes should have secured an investigational device exemption before soliciting information from physicians on patient experiences with the firm's Norian XR calcium phosphate bone void filler, according to a recent FDA warning letter
You may also be interested in...
Synthes Charged With Unauthorized Spine Repair Trial, Faces $34 Mil. Fine
Orthopedic device maker Synthes and its Norian subsidiary face $34.8 million in potential fines for allegedly skirting FDA requirements and conducting unauthorized clinical trials of their Norian XR and Norian SRS bone cement for vertebral compression fractures
Synthes Charged With Unauthorized Spine Repair Trial, Faces $34 Mil. Fine
Orthopedic device maker Synthes and its Norian subsidiary face $34.8 million in potential fines for allegedly skirting FDA requirements and conducting unauthorized clinical trials of their Norian XR and Norian SRS bone cement for vertebral compression fractures
SYNTHES SPINAL INSTRUMENT PROCESS VALIDATION GMP DEFICIENCIES
SYNTHES SPINAL INSTRUMENT PROCESS VALIDATION GMP DEFICIENCIES result in receipt of a warning letter from FDA. Following inspections of the company's Exton and Paoli, Pennsylvania facilities conducted Aug. 9-26, the agency concluded in the Sept. 23 letter that the company's process validation procedures are not "adequate to assure product integrity."